Quantitative imaging biomarkers in neuro-oncology

Nature Reviews Clinical Oncology

Volumn 6, Issue 8, 2009, Pages 445-454

  Waldman, Adam D ^a   Jackson, Alan ^b   Price, Stephen J ^c   Clark, Christopher A ^d   Booth, Thomas C ^e   Auer, Dorothee P ^f   Tofts, Paul S ^g   Collins, David J ^h   Leach, Martin O ^h   Rees, Jeremy H ⁱ  

^a CHARING CROSS HOSPITAL   (United Kingdom)

^b University of Manchester   (United Kingdom)

^c ADDENBROOKE S HOSPITAL   (United Kingdom)

^d UNIVERSITY COLLEGE LONDON   (United Kingdom)

^e ROYAL FREE HOSPITAL   (United Kingdom)

^f UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^g BRIGHTON AND SUSSEX MEDICAL SCHOOL   (United Kingdom)

^h ROYAL MARSDEN HOSPITAL   (United Kingdom)

ⁱ UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CARBON 11; CARBOPLATIN; CEDIRANIB; FLUORODEOXYGLUCOSE F 18; METHIONINE C 11; OXYGEN; TEMOZOLOMIDE; THALIDOMIDE; VASCULOTROPIN; ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; DEOXYHEMOGLOBIN; HEMOGLOBIN;

BLOOD VESSEL PERMEABILITY; BRAIN ABSCESS; BRAIN BLOOD FLOW; BRAIN CANCER; BRAIN REGION; BRAIN TUMOR; CANCER GRADING; CONTRAST ENHANCEMENT; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; DIFFUSION TENSOR IMAGING; DIFFUSION WEIGHTED IMAGING; DISEASE MARKER; DISEASE SEVERITY; DRUG EFFICACY; DRUG TARGETING; GLIOMA; HUMAN; MOLECULAR IMAGING; NEUROIMAGING; NEUROSURGERY; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; OXYGEN BLOOD LEVEL; PERFUSION WEIGHTED IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIMARY TUMOR; PRIORITY JOURNAL; PROGNOSIS; QUANTITATIVE ANALYSIS; RADIATION RESPONSE; REVIEW; SECOND CANCER; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; STEREOTACTIC BIOPSY; TREATMENT PLANNING; TREATMENT RESPONSE; TUMOR BLOOD FLOW; TUMOR GROWTH; TUMOR SCINTISCANNING; TUMOR VOLUME; ULTRASTRUCTURE; BLOOD; BLOOD VOLUME; BRAIN CIRCULATION; BRAIN DISEASE; BRAIN LEVEL; CHEMISTRY; DRUG DELIVERY SYSTEM; METASTASIS; METHODOLOGY; NEOVASCULARIZATION (PATHOLOGY); ORGANIZATION AND MANAGEMENT; PATHOLOGY; SENSITIVITY AND SPECIFICITY; VASCULARIZATION;

ANTINEOPLASTIC AGENTS; BIOLOGICAL MARKERS; BLOOD VOLUME; BRAIN CHEMISTRY; BRAIN DISEASES; BRAIN NEOPLASMS; CEREBROVASCULAR CIRCULATION; DIAGNOSIS, DIFFERENTIAL; DRUG DELIVERY SYSTEMS; GLIOMA; HEMOGLOBINS; HUMANS; MAGNETIC RESONANCE IMAGING; NEOVASCULARIZATION, PATHOLOGIC; NEUROSURGICAL PROCEDURES; OXYGEN; PLANNING TECHNIQUES; POSITRON-EMISSION TOMOGRAPHY; SENSITIVITY AND SPECIFICITY;

EID: 70350010318     PISSN: 17594774     EISSN: 17594782     Source Type: Journal    
DOI: 10.1038/nrclinonc.2009.92     Document Type: Review

References (110)

1. sorensen, A. G. et al. Comparison of diameter and perimeter methods for tumor volume calculation. J. Clin. Oncol. 19, 551-557 (2001).
2. Tate, A. et al. Automated classification of short echo time in in vivo 1H brain tumor spectra: a multicenter study. Magn. Reson. Med. 49, 29-36 (2003).
3. Preul, M., Caramanos, Z., Leblanc, r., villemure, J. G. & Arnold, D. L. Using pattern analysis of in vivo proton Mrsi data to improve the diagnosis and surgical management of patients with brain tumors. NMR Biomed. 11, 192-200 (1998).
4. Devos, A. et al. Classification of brain tumours using short echo time 1H Mr spectra. J. Magn. Reson. 170, 164-175 (2004).
5. sadeghi, N. et al. effect of hydrophilic components of the extracellular matrix on quantifiable diffusion-weighted imaging of human gliomas: preliminary results of correlating apparent diffusion coefficient values and hyaluronan expression level. AJR Am. J. Roentgenol. 181, 235-241 (2003).
6. Omuro, A., Leite, C. C., Mokhtari, K. & Delattre, J. Y. Pitfalls in the diagnosis of brain tumours. Lancet Neurol. 5, 937-948 (2006).
7. Fertikh, D. et al. Discrimination of capsular stage brain abscesses from necrotic or cystic neoplasms using diffusion-weighted magnetic resonance imaging. J. Neurosurg. 106, 76-81 (2007).
8. Nadal Desbarats, L. et al. Differential Mri diagnosis between brain abscesses and necrotic or cystic brain tumors using the apparent diffusion coefficient and normalized diffusion-weighted images. Magn. Reson. Imaging 21, 645-650 (2003).
9. erdogan, C., Hakyemez, B., Yildirim, N. & Parlak, M. Brain abscess and cystic brain tumor: discrimination with dynamic susceptibility contrast perfusion-weighted Mri. J. Comput. Assist. Tomogr. 29, 663-667 (2005).
10. Holmes, T., Petrella, J. r. & Provenzale, J. M. Distinction between cerebral abscesses and high-grade neoplasms by dynamic susceptibility contrast perfusion Mri. AJR Am. J. Roentgenol. 183, 1247-1252 (2004).
11. Law, M. et al. Differentiating surgical from non-surgical lesions using perfusion Mr imaging and proton Mr spectroscopic imaging. Technol. Cancer Res. Treat. 3, 557-565 (2004).
12. Bink, A. et al. importance of diffusion-weighted imaging in the diagnosis of cystic brain tumors and intracerebral abscesses. Zentralbl. Neurochir. 66, 119-125 (2005).
13. Mascalchi, M. et al. Diffusion-weighted Mr of the brain: methodology and clinical application. Radiol. Med. 109, 155-197 (2005).
14. Cha, s. et al. Dynamic contrast-enhanced T2&-weighted Mr imaging of tumefactive demyelinating lesions. AJNR Am. J. Neuroradiol. 22, 1109-1116 (2001).
15. De stefano, N. et al. In vivo differentiation of astrocytic brain tumors and isolated demyelinating lesions of the type seen in multiple sclerosis using 1H magnetic resonance spectroscopic imaging. Ann. Neurol. 44, 273-278 (1998).
16. Law, M., Meltzer, D. e. & Cha, s. spectroscopic magnetic resonance imaging of a tumefactive demyelinating lesion. Neuroradiology 44, 986-989 (2002).
17. Herholz, K. et al. 11C methionine PeT for differential diagnosis of low-grade gliomas. Neurology 50, 1316-1322 (1998).
18. rollin, N. et al. Clinical relevance of diffusion and perfusion magnetic resonance imaging in assessing intra-axial brain tumors. Neuroradiology 48, 150-159 (2006).
19. strugar, J., rothbart, D., Harrington, w. & Criscuolo, G. r. vascular permeability factor in brain metastases: correlation with vasogenic brain edema and tumor angiogenesis. J. Neurosurg. 81, 560-566 (1994).
20. strugar, J., Criscuolo, G. r., rothbart, D. & Harrington, w. N. vascular endothelial growth/ permeability factor expression in human glioma specimens: correlation with vasogenic brain edema and tumor-associated cysts. J. Neurosurg. 83, 682-689 (1995).
21. Lu, s. et al. Diffusion-tensor Mr imaging of intracranial neoplasia and associated peritumoral edema: introduction of the tumor infiltration index. Radiology 232, 221-228 (2004).
22. Chiang, i. et al. Distinction between high-grade gliomas and solitary metastases using peritumoral 3 T magnetic resonance spectroscopy, diffusion, and perfusion imagings. Neuroradiology 46, 619-627 (2004).
23. Kleihues, P. and Cavanee, w. K. (eds) World Health Organization Classification of Tumours: Pathology and Genetics: Tumours of the Nervous System (iArC, Lyon, 2000).
24. Tozer, D. et al. Apparent diffusion coefficient histograms may predict low-grade glioma subtype. NMR Biomed. 20, 49-57 (2007).
25. Cha, s. et al. Differentiation of low-grade oligodendrogliomas from low-grade astrocytomas by using quantitative blood-volume measurements derived from dynamic susceptibility contrast-enhanced Mr imaging. AJNR Am. J. Neuroradiol. 26, 266-273 (2005).
26. Lev, M. H. et al. Glial tumor grading and outcome prediction using dynamic spin-echo Mr susceptibility mapping compared with conventional contrast-enhanced Mr: confounding effect of elevated rCBv of oligodendrogliomas [corrected]. AJNR Am. J. Neuroradiol 25, 214-221 (2004).
27. sugahara, T. et al. value of dynamic susceptibility contrast magnetic resonance imaging in the evaluation of intracranial tumors. Top. Magn. Reson. Imaging 10, 114-124 (1999).
28. Cha, s. et al. intracranial mass lesions: dynamic contrast-enhanced susceptibility-weighted echoplanar perfusion Mr imaging. Radiology 223, 11-29 (2002).
29. Calli, C. et al. Perfusion and diffusion Mr imaging in enhancing malignant cerebral tumors. Eur. J. Radiol. 58, 394-403 (2006).
30. weber, M. A. et al. Diagnostic performance of spectroscopic and perfusion Mri for distinction of brain tumors. Neurology 66, 1899-1906 (2006).
31. Yang, s. et al. Dynamic contrast-enhanced perfusion Mr imaging measurements of endothelial permeability: differentiation between atypical and typical meningiomas. AJNR Am. J. Neuroradiol. 24, 1554-1559 (2003). (Pubitemid 37151719)
32. Filippi, C. G. et al. Appearance of meningiomas on diffusion-weighted images: correlating diffusion constants with histopathologic findings. AJNR Am. J. Neuroradiol. 22, 65-72 (2001).
33. Law, M. Mr spectroscopy of brain tumors. Top. Magn. Reson. Imaging 15, 291-313 (2004).
34. Kremer, s. et al. Contribution of dynamic contrast Mr imaging to the differentiation between dural metastasis and meningioma. Neuroradiology 46, 642-648 (2004).
35. stupp, r. et al. radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med. 352, 987-996 (2005).
36. sugahara, T. et al. Correlation of Mr imagingdetermined cerebral blood volume maps with histologic and angiographic determination of vascularity of gliomas. AJR Am. J. Roentgenol. 171, 1479-1486 (1998).
37. Maia, A. et al. Mr cerebral blood volume maps correlated with vascular endothelial growth factor expression and tumor grade in nonenhancing gliomas. AJNR Am. J. Neuroradiol. 26, 777-783 (2005).
38. Law, M. et al. Comparison of cerebral blood volume and vascular permeability from dynamic susceptibility contrast-enhanced perfusion Mr imaging with glioma grade. AJNR Am. J. Neuroradiol. 25, 746-755 (2004).
39. Law, M. et al. Glioma grading: sensitivity, specificity, and predictive values of perfusion Mr imaging and proton Mr spectroscopic imaging compared with conventional Mr imaging. AJNR Am. J. Neuroradiol. 24, 1989-1998 (2003).
40. Cha, s. et al. Comparison of microvascular permeability measurements, Ktrans, determined with conventional steady-state T1-weighted and first-pass T2&-weighted Mr imaging methods in gliomas and meningiomas. AJNR Am. J. Neuroradiol. 27, 409-417 (2006).
41. Patankar, T. F. et al. is volume transfer coefficient (Ktrans) related to histologic grade in human gliomas? AJNR Am. J. Neuroradiol. 26, 2455-2465 (2005).
42. sugahara, T. et al. Usefulness of diffusionweighted Mri with echo-planar technique in the evaluation of cellularity in gliomas. J. Magn. Reson. Imaging 9, 53-60 (1999).
43. Yang, D. et al. Cerebral gliomas: prospective comparison of multivoxel 2D chemical-shift imaging proton Mr spectroscopy, echoplanar perfusion and diffusion-weighted Mri. Neuroradiology 44, 656-666 (2002).
44. Lam, w. w., Poon, w. s. & Metreweli, C. Diffusion Mr imaging in glioma: does it have any role in the pre-operation determination of grading of glioma? Clin. Radiol. 57, 219-225 (2002).
45. stadlbauer, A. et al. Gliomas: histopathologic evaluation of changes in directionality and magnitude of water diffusion at diffusion-tensor Mr imaging. Radiology 240, 803-810 (2006).
46. Hourani, r. et al. Can proton Mr spectroscopic and perfusion imaging differentiate between neoplastic and nonneoplastic brain lesions in adults? AJNR Am. J. Neuroradiol. 29, 366-372 (2008).
47. Howe, F. A. et al. Metabolic profiles of human brain tumors using quantitative in vivo 1H magnetic resonance spectroscopy. Magn. Reson. Med. 49, 223-232 (2003).
48. stadlbauer, A. et al. Preoperative grading of gliomas by using metabolite quantification with high-spatial-resolution proton Mr spectroscopic imaging. Radiology 238, 958-969 (2006).
49. McKnight, T. r. et al. Correlation of magnetic resonance spectroscopic and growth characteristics within grades ii and iii gliomas. J. Neurosurg. 106, 660-666 (2007).
50. Price, s. J. et al. Diffusion tensor imaging of brain tumours at 3 T: a potential tool for assessing white matter tract invasion? Clin. Radiol. 58, 455-462 (2003).
51. Pallud, J. et al. Prognostic value of initial magnetic resonance imaging growth rates for world Health Organization grade ii gliomas. Ann. Neurol. 60, 380-383 (2006).
52. rees, J. et al. volumes and growth rates of untreated adult low-grade gliomas indicate risk of early malignant transformation. Eur. J. Radiol. doi:10.1016/j.ejrad.2008.06.013.
53. Law, M. et al. Low-grade gliomas: dynamic susceptibility-weighted contrast-enhanced perfusion Mr imaging-prediction of patient clinical response. Radiology 238, 658-667 (2006).
54. Danchaivijitr, N. et al. Low-grade gliomas: do changes in rCBv measurements at longitudinal perfusion-weighted Mr imaging predict malignant transformation? Radiology 247, 170-178 (2008).
55. van den Bent, M. J. et al. Adjuvant procarbazine, lomustine, and vincristine improves progressionfree survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized european Organisation for research and Treatment of Cancer phase iii trial. J. Clin. Oncol. 24, 2715-2722 (2006).
56. intergroup radiation Therapy Oncology Group Trial 9402, Cairncross, G. et al. Phase iii trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: intergroup radiation Therapy Oncology Group Trial 9402. J. Clin. Oncol. 24, 2707-2714 (2006).
57. Jenkinson, M. et al. Cerebral blood volume, genotype and chemosensitivity in oligodendroglial tumours. Neuroradiology 48, 703-713 (2006).
58. Megyesi, J. F. et al. imaging correlates of molecular signatures in oligodendrogliomas. Clin. Cancer Res. 10, 4303-4306 (2004).
59. Brown, r. et al. The use of magnetic resonance imaging to noninvasively detect genetic signatures in oligodendroglioma. Clin. Cancer Res. 14, 2357-2362 (2008).
60. Aghi, M. et al. Magnetic resonance imaging characteristics predict epidermal growth factor receptor amplification status in glioblastoma. Clin. Cancer Res. 11, 8600-8605 (2005).
61. Aronen, H. J. et al. High microvascular blood volume is associated with high glucose uptake and tumor angiogenesis in human gliomas. Clin. Cancer Res. 6, 2189-2200 (2000).
62. Pirotte, B. et al. integrated positron emission tomography and magnetic resonance imagingguided resection of brain tumors: a report of 103 consecutive procedures. J. Neurosurg. 104, 238-253 (2006).
63. McKnight, T. r. et al. Histopathological validation of a three-dimensional magnetic resonance spectroscopy index as a predictor of tumor presence. J. Neurosurg. 97, 794-802 (2002).
64. Ganslandt, O. et al. Proton magnetic resonance spectroscopic imaging integrated into imageguided surgery: correlation to standard magnetic resonance imaging and tumor cell density. Neurosurgery 56 (Suppl. 2), 291-298 (2005).
65. Di Costanzo, A. et al. Multiparametric 3 T Mr approach to the assessment of cerebral gliomas: tumor extent and malignancy. Neuroradiology 48, 622-631 (2006).
66. witwer, B. P. et al. Diffusion tensor imaging of white matter tracts in patients with cerebral neoplasm. J. Neurosurg. 97, 568-575 (2002).
67. Clark, C. A., Barrick, T. r., Murphy, M. M. & Bell, B. A. white matter fiber tracking in patients with space-occupying lesions of the brain: a new technique for neurosurgical planning? Neuroimage 20, 1601-1608 (2003).
68. Nimsky, C. et al. Preoperative and intraoperative diffusion tensor imaging-based fiber tracking in glioma surgery. Neurosurgery 56, 130-137 (2005).
69. Bello, L. et al. Motor and language DTi fiber tracking combined with intraoperative subcortical mapping for surgical removal of gliomas. Neuroimage 39, 369-382 (2008).
70. Pujol, J. et al. identification of the sensorimotor cortex with functional Mri: frequency and actual contribution in a neurosurgical context. J. Neuroimaging 18, 28-33 (2008).
71. Ojemann, G., Ojemann, J., Lettich, e. & Berger, M. Cortical language localization in left, dominant hemisphere. An electrical stimulation mapping investigation in 117 patients. J. Neurosurg. 71, 316-326 (1989).
72. Bizzi, A. et al. Presurgical functional Mr imaging of language and motor functions: validation with intraoperative electrocortical mapping. Radiology 248, 579-589 (2008).
73. Krings, T. et al. Metabolic and electrophysiological validation of functional Mri. J. Neurol. Neurosurg. Psychiatry 71, 762-771 (2001).
74. Ulmer, J. L. et al. Pseudo-reorganization of language cortical function at fMr imaging: a consequence of tumor-induced neurovascular uncoupling. AJNR Am. J. Neuroradiol. 24, 213-217 (2003).
75. roux, F. e. et al. Language functional magnetic resonance imaging in preoperative assessment of language areas: correlation with direct cortical stimulation. Neurosurgery 52, 1335-1345 (2003).
76. rutten, G., ramsey, N. F., van rijen, P. C. & van veelen, C. w. reproducibility of fMridetermined language lateralization in individual subjects. Brain Lang. 80, 421-437 (2002).
77. Lee, C. C. et al. Assessment of functional Mr imaging in neurosurgical planning. AJNR Am. J. Neuroradiol. 20, 1511-1519 (1999).
78. Chan, A. A. et al. Proton magnetic resonance spectroscopy imaging in the evaluation of patients undergoing gamma knife surgery for grade iv glioma. J. Neurosurg. 101, 467-475 (2004).
79. Jena, r. et al. Diffusion tensor imaging: possible implications for radiotherapy treatment planning of patients with high grade glioma. Clin. Oncol. (R. Coll. Radiol.) 17, 581-590 (2005).
80. Maruyama, K. et al. Optic radiation tractography integrated into simulated treatment planning for gamma knife surgery. J. Neurosurg. 107, 721-726 (2007).
81. Grosu, A. L. et al. l-(methyl-11C) methionine positron emission tomography for target delineation in resected high-grade gliomas before radiotherapy. Int. J. Radiat. Oncol. Biol. Phys. 63, 64-74 (2005).
82. Grosu, A. L. et al. reirradiation of recurrent high grade gliomas using amino acid PeT (sPeCT)/ CT/Mri image fusion to determine gross tumor volume for stereotactic fractionated radiotherapy. Int. J. Radiat. Oncol. Biol. Phys. 63, 511-519 (2005).
83. MacDonald, D., Cascino, T. L., schold, s. C. Jr & Cairncross, J. G. response criteria for phase ii studies of supratentorial malignant glioma. J. Clin. Oncol. 8, 1277-1280 (1990).
84. shah, G. D. et al. Comparison of linear and volumetric criteria in assessing tumor response in adult high-grade gliomas. Neuro Oncol. 8, 38-46 (2006).
85. Dempsey, M., Condon, B. r. & Hadley, D. M. Measurement of tumor "size" in recurrent malignant glioma: 1D, 2D, or 3D? AJNR Am. J. Neuroradiol. 26, 770-776 (2005).
86. Brandsma, D., stalpers, L., Taal, w., sminia, P. & van den Bent, M. J. Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas. Lancet Oncol. 9, 453-461 (2008).
87. Mathews, M., Linskey, M. e., Hasso, A. N. & Fruehauf, J. P. The effect of bevacizumab (Avastin) on neuroimaging of brain metastases. Surg. Neurol. 70, 649-652 (2008).
88. Hsu, Y. et al. Blood oxygenation level-dependent Mri of cerebral gliomas during breath holding. J. Magn. Reson. Imaging 19, 160-167 (2004).
89. Cher, L. M. et al. Correlation of hypoxic cell fraction and angiogenesis with glucose metabolic rate in gliomas using 18F-fluoromisonidazole, 18F-FDG PeT, and immunohistochemical studies. J. Nucl. Med. 47, 410-418 (2006).
90. ribom, D., engler, H., Blomquist, e. & smits, A. Potential significance of 11C-methionine PeT as a marker for the radiosensitivity of low grade gliomas. Eur. J. Nucl. Med. Mol. Imaging 29, 632-640 (2002).
91. Moffat, B. A. et al. Functional diffusion map: a noninvasive Mri biomarker for early stratification of clinical brain tumor response. Proc. Natl Acad. Sci. USA 102, 5524-5529 (2005).
92. Cao, Y. et al. survival prediction in high-grade gliomas by Mri perfusion before and during early stage of rT [corrected]. Int. J. Radiat. Oncol. Biol. Phys. 64, 876-885 (2006).
93. Herholz, K., Coope, D. & Jackson, A. Metabolic and molecular imaging in neuro-oncology. Lancet Neurol. 6, 711-724 (2007).
94. wald, L. L. et al. serial proton magnetic resonance spectroscopy imaging of glioblastoma multiforme after brachytherapy. J. Neurosurg. 87, 525-534 (1997).
95. Graves, e. e. et al. serial proton Mr spectroscopic imaging of recurrent malignant gliomas after gamma knife radiosurgery. AJNR Am. J. Neuroradiol. 22, 613-624 (2001).
96. Hollingworth, w. et al. A systematic literature review of magnetic resonance spectroscopy for the characterization of brain tumors. AJNR Am. J. Neuroradiol. 27, 1404-1411 (2006).
97. Zeng, Q. s. et al. Multivoxel 3D proton Mr spectroscopy in the distinction of recurrent glioma from radiation injury. J. Neurooncol. 84, 63-69 (2007).
98. sugahara, T. et al. Posttherapeutic intraaxial brain tumor: the value of perfusion-sensitive contrast-enhanced Mr imaging for differentiating tumor recurrence from nonneoplastic contrastenhancing tissue. AJNR Am. J. Neuroradiol. 21, 901-909 (2000).
99. ricci, P. e. et al. Differentiating recurrent tumor from radiation necrosis: time for re-evaluation of positron emission tomography? AJNR Am. J. Neuroradiol. 19, 407-413 (1998).
100. Tsuyuguchi, N. et al. Methionine positron emission tomography for differentiation of recurrent brain tumor and radiation necrosis after stereotactic radiosurgery in malignant glioma. Ann. Nucl. Med. 18, 291-296 (2004).
101. rachinger, w. et al. Positron emission tomography with O-(2-[18F]fluoroethyl)-l-tyrosine versus magnetic resonance imaging in the diagnosis of recurrent gliomas. Neurosurgery 57, 505-511 (2005).
102. Murphy, P. s. et al. Monitoring temozolomide treatment of low-grade glioma with proton magnetic resonance spectroscopy. Br. J. Cancer 90, 781-786 (2004).
103. Brock, C. s. et al. early evaluation of tumour metabolic response using [18F] fluorodeoxyglucose and positron emission tomography: a pilot study following the phase ii chemotherapy schedule for temozolomide in recurrent high-grade gliomas. Br. J. Cancer 82, 608-615 (2000).
104. Charnley, N. et al. early change in glucose metabolic rate measured using FDG-PeT in patients with high grade glioma predicts response to temozolomide but not temozolomide plus radiotherapy. Int. J. Radiat. Oncol. Biol. Phys. 66, 331-338 (2006).
105. Galldiks, N. et al. Use of 11C-methionine PeT to monitor the effects of temozolomide chemotherapy in malignant gliomas. Eur. J. Nucl. Med. Mol. Imaging 33, 516-524 (2006).
106. Chen, w. et al. Predicting treatment response of malignant gliomas to bevacizumab and irinotecan by imaging proliferation with [18F] fluorothymidine positron emission tomography: a pilot study. J. Clin. Oncol. 25, 4714-4721 (2007).
107. O'Connor, J. P., Jackson, A., Parker, G. J. & Jayson, G. C. DCe-Mri biomarkers in the clinical evaluation of antiangiogenic and vascular disrupting agents. Br. J. Cancer 96, 189-195 (2007).
108. Cha, s. et al. Dynamic contrast-enhanced T2-weighted Mr imaging of recurrent malignant gliomas treated with thalidomide and carboplatin. AJNR Am. J. Neuroradiol. 21, 881-890 (2000).
109. Batchelor, T. T. et al. AZD2171, a pan-veGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell 11, 83-95 (2007).
110. Armitage, P., schwindack, C., Bastin, M. e. & whittle, i. r. Quantitative assessment of intracranial tumor response to dexamethasone using diffusion, perfusion and permeability magnetic resonance imaging. Magn. Reson. Imaging 25, 303-310 (2007).